DERMAVANT HOLDINGS LIMITED

10317657
Active Cramlington

Non-trading company

0 employees website.com
Life sciences and medical technology Non-trading company
D

DERMAVANT HOLDINGS LIMITED

10317657

Non-trading company

Founded 8 Aug 2016 Active Cramlington, United Kingdom 0 employees website.com
Life sciences and medical technology Non-trading company
Accounts Submitted 19 Feb 2026 Next due 31 Dec 2025 7 months overdue
Confirmation Submitted 19 Aug 2025 Next due 22 Aug 2026 1 month remaining
Net assets £69M £69M 2024 year on year
Total assets £70M £69M 2024 year on year
Total Liabilities £177K £145K 2024 year on year
Charges 5
5 satisfied

Contact & Details

Contact

Registered Address

Organon Pharma (Uk) Limited Shotton Lane Cramlington NE23 3JU United Kingdom

Email

info@example.com

Website

www.example.com

Full company profile for DERMAVANT HOLDINGS LIMITED (10317657), an active life sciences and medical technology company based in Cramlington, United Kingdom. Incorporated 8 Aug 2016. Non-trading company. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2024
Due by 31 Dec 2025 7 months overdue

Net Assets, Total Assets & Total Liabilities (2016–2024)

Cash in Bank

£91.84k

Increased by £55.44k (+152%)

Net Assets

£69.40M

Increased by £69.14M (+26311%)

Total Liabilities

£176.50k

Increased by £144.84k (+457%)

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Decreased by 11 (-100%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2024
31 Mar Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

6 Allotments 6 Shares £561k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
30 Mar 20231$188k$188k
29 Mar 20221$198k$198k
29 Mar 20221$40k$40k
31 Mar 20211$60k$60k
31 Mar 20201$15k$15k

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Dermavant Sciences Ltd
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Organon & Co.

United States Of America

Active
Notified 28 Oct 2024
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent

Roivant Sciences Ltd.

Ceased 28 Oct 2024

Ceased

Group Structure

Group Structure

DERMAVANT HOLDINGS LIMITED Current Company

Charges

Charges

5 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
9 Jun 2026OfficersTermination of John Albert Parsons as director on 31 May 2026
9 Jun 2026OfficersAppointment of Marie-Catherine Barberoux as director on 1 Jun 2026
19 Feb 2026AccountsAnnual accounts made up to 31 Dec 2024
25 Sept 2025OfficersAppointment of Nicola Barr as director on 1 Sept 2025
10 Sept 2025OfficersAppointment of Anne Bitzer as director on 1 Sept 2025
9 Jun 2026 Officers

Termination of John Albert Parsons as director on 31 May 2026

9 Jun 2026 Officers

Appointment of Marie-Catherine Barberoux as director on 1 Jun 2026

19 Feb 2026 Accounts

Annual accounts made up to 31 Dec 2024

25 Sept 2025 Officers

Appointment of Nicola Barr as director on 1 Sept 2025

10 Sept 2025 Officers

Appointment of Anne Bitzer as director on 1 Sept 2025

Recent Activity

Latest Activity

Termination of John Albert Parsons as director on 31 May 2026

3 weeks ago on 9 Jun 2026

Appointment of Marie-Catherine Barberoux as director on 1 Jun 2026

3 weeks ago on 9 Jun 2026

Annual accounts made up to 31 Dec 2024

4 months ago on 19 Feb 2026

Appointment of Nicola Barr as director on 1 Sept 2025

9 months ago on 25 Sept 2025

Appointment of Anne Bitzer as director on 1 Sept 2025

9 months ago on 10 Sept 2025